Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) (“Portola " or the “Company”) for violations of federal securities laws.
|
SAN DIEGO, Jan. 10, 2020 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) ("Portola " or the "Company") for violations of federal securities laws. On January 9, 2020, Portola announced that the drug, Andexxa, brought in about $28 million in revenue in the fourth quarter of 2019. Oppenheimer's analyst covering the stock wrote Andexxa's fourth-quarter revenues "were well below our $39 million estimate and $41 million consensus". Following this news, on January 10, 2020, Portola stock was down over 43% in early morning trading. If you lost money, realized or unrealized on your Portola investment, and are interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471. If emailing, please include a phone number. Additionally, you can [click here to join this action]. There is no cost or obligation to you. About Johnson Fistel, LLP: Contact: [click here to join this action]
SOURCE Johnson Fistel, LLP |
||
Company Codes: NASDAQ-NMS:PTLA |
View original content:
